Emerging Strategies in Hemophilia: Restoring the Hemostatic Balance

Please note: You must be registered to attend the 2022 Thrombosis & Hemostasis Summit of North America (THSNA) to attend this symposium. You may register at: https://www.thsna.org/2022/attend-registration.php

Join us for an interactive symposium on emerging strategies for managing hemophilia A and B aimed at restoring hemostatic balance.  

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.


6:30 AM – 6:45 AM Breakfast & Registration

6:45 AM – 6:50 AM Welcome and Introduction

6:50 AM – 7:05 AM New Advances in the Treatment Landscape for Hemophilia and Unmet Clinical Need

7:05 AM – 7:25 AM The Future of Hemophilia Therapy: Restoring the Hemostatic Balance

7:25 AM – 7:35 AM Panel Discussion

7:35 AM – 7:45 AM Audience Question & Answer Session


Date / Time
Event Details


Program Chair
Guy A. Young, MD

Professor of Pediatrics
, Hemostasis and Thrombosis Center
Children's Hospital Los Angeles
University of Southern California Keck School of Medicine
Los Angeles, California

Glaivy Batsuli, MD

Assistant Professor of Pediatrics
Pediatric Hematologist
Division of Pediatric Hematology and Oncology
Department of Pediatrics
Emory University and Children's Healthcare of Atlanta
Atlanta, Georgia

Allison P. Wheeler, MD

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners in using new and emerging therapeutic options for patients with hemophilia A and B.

Target Audience
This program is intended for hematologists and other healthcare professionals who care for patients with hemophilia A and B.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the engineered mechanism by which new therapies for hemophilia A and B can restore hemostatic balance
  • Evaluate the available data for investigational hemophilia agents and their ability to improve patient outcomes without introducing new health risks
  • Identify patients with hemophilia A or B who may be eligible for enrollment on a clinical trial investigating agents that target anticoagulant pathways or next-generation bispecific antibodies
  • Integrate hemophilia therapies that aim to restore hemostatic balance into clinical practice as they become available


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.